EKF Diagnostics Holdings plc

LSE:EKF.L

Sector

🏥 Health Care

Industries

🩺 Medical Instruments

🧬 Biotechnology

🔬 Clinical Trials

🏬 Consumer Packaged Goods

💻 Telehealth

Location

United Kingdom

Market Cap

USD 160.55 M

Share Price

USD 0.36

Avg Daily Volume

583,529

Change (1 day)

0.63%

Change (1 year)

-0.15%

Change (YTD)

5.49%

EKF Diagnostics Holdings plc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2024: USD 17.11 M

EKF Diagnostics Holdings plc Selling, General, and Administrative Expenses (SG&A) is USD 17.11 M for the year ending December 31, 2024, a -24.79% change year over year. Selling, general, and administrative (SG&A) expenses are the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company.

EKF Diagnostics Holdings plc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2023 was USD 22.75 M, a -18.78% change year over year.
EKF Diagnostics Holdings plc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2022 was USD 28.01 M, a 16.89% change year over year.
EKF Diagnostics Holdings plc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2021 was USD 23.96 M, a -15.05% change year over year.
EKF Diagnostics Holdings plc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2020 was USD 28.21 M, a 16.47% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Selling, General, and Administrative Expenses (SG&A)	Research and Development (R&D) Expenses	Revenue	Revenue

LSE: EKF.L

EKF Diagnostics Holdings plc

CEO	Mr. Gavin Joseph Jones
IPO Date	Jan. 4, 2000
Location	United Kingdom
Headquarters	Avon House
Employees	303
Sector	🏥 Health Care
Industries Medical Instruments 🧬 Biotechnology 🔬 Clinical Trials 🏬 Consumer Packaged Goods 💻 Telehealth

Description

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.